Search clinical trials for: BG00012 placebo

Total 54087 results

Biogen

Completed

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Healthy | Painful Lumbar Radiculopathy

Netherlands
Biogen

Completed

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy (SPRINT)

Sciatica | Radiculopathy | Painful Lumbar Radiculopathy

United States
Biogen

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

Sciatica

Netherlands
Biogen

Terminated

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis (SPIRIT)

Idiopathic Pulmonary Fibrosis

United States, Italy, Belgium, Czechia, Russian Federation, Korea, Republic of, Australia, France, Israel, Spain, Poland, Netherlands, Denmark, Greece, Argentina, Chile, United Kingdom
Biogen

Completed

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

United States
Biogen

Completed

Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants

Sciatica

Australia
Biogen

Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (STRATEGY)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers (109HV108)

Healthy

Australia, China
Biogen

Completed

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke (ACTION2)

Acute Ischemic Stroke

Spain, United States, Germany, United Kingdom
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Biogen

Withdrawn

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
Biogen

Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Korea, Republic of, Taiwan, Czechia, Japan, Poland
Biogen

Completed

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

Healthy

United States
Biogen

Completed

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION)

Acute Ischemic Stroke

Spain, United States, Germany
Biogen
GB Pharma Services & Consulting s.r.l.

Withdrawn

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis (PROMPT)

Relapsing Remitting Multiple Sclerosis
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Biogen

Completed

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (Tysabri Japan)

Multiple Sclerosis

Japan
Biogen

Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Multiple Sclerosis, Relapsing-Remitting

Mexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
Biogen

Completed

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Czech Republic, Poland, Slovakia, India, Australia, Canada
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

Spain, Switzerland, Ireland, United States, Germany
Biogen

Terminated

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)

Multiple Sclerosis, Secondary Progressive

United States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia
Biogen

Completed

Alternate Dosing Regimens of BG00012 in Healthy Volunteers (109HV106)

Healthy

United States
Biogen

Completed

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

Healthy
Biogen

Completed

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (FOCUS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Biogen

Terminated

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Japan
Multiple Sclerosis Center of Northeastern New York
Biogen

Completed

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Multiple Sclerosis

United States
Biogen

Completed

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Relapsing Remitting Multiple Sclerosis

Germany
Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Biogen

Completed

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Belgium, Turkey, Bulgaria, United States, Czechia, Germany, Kuwait, Latvia, Lebanon
Biogen

Completed

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (StarTec)

Multiple Sclerosis, Relapsing-Remitting

Italy
Biogen

Completed

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (TOLERATE)

Relapsing-Remitting Multiple Sclerosis

Germany
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Biogen

Terminated

Tecfidera Slow-Titration Study (TITRATION)

Multiple Sclerosis

United States, Belgium, Czech Republic, Italy
Biogen

Completed

BG00012 Regional Absorption Study

Healthy

United Kingdom
Biogen

Completed

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Healthy

United States
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Biogen
Elan Pharmaceuticals

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (TIMER)

Relapsing Remitting Multiple Sclerosis (RRMS)

Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (MANAGE)

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Tecfidera Lymphocyte Chart Review (REALIZE)

Multiple Sclerosis

United States
Biogen

Completed

Ireland Natalizumab (TYSABRI) Observational Program (iTOP)

Relapsing-Remitting Multiple Sclerosis

Ireland
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
Biogen

Completed

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Bulgaria, Belgium, Poland, Lithuania, Kuwait, Turkey

Search clinical trials for: BG00012 placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations